Skip to main content
Top
Published in: Virology Journal 1/2007

Open Access 01-12-2007 | Research

In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter

Authors: Agustín Luz-Madrigal, Carmen Clapp, Jorge Aranda, Luis Vaca

Published in: Virology Journal | Issue 1/2007

Login to get access

Abstract

Background

Endothelial cells are a target for gene therapy because they are implicated in a number of vascular diseases. Recombinant baculovirus have emerged as novel gene delivery vectors. However, there is no information available concerning the use of endothelial-specific promoters in the context of the baculovirus genome. In the present study, we have generated a recombinant baculovirus containing the human flt-1 promoter (BacFLT-GFP) driving the expression of the green fluorescent protein. Transcriptional gene targeting was analyzed in vitro in different mammalian cell lines and in vivo in adult rat retinal vasculature.

Results

BacFLT-GFP evoked the highest levels of expression in the endothelial cell line BUVEC-E6E7-1, similar to those reached by recombinant baculovirus carrying the CMV promoter (112% relative to BacCMV-GFP, n = 4). Interestingly, BacFLT-GFP directed high levels of expression in rat glioma C6 and in human glioblastoma CH235 cells (34.78% and 47.86% relative to BacCMV-GFP, respectively). Histone deacetylase inhibitors such as butyrate or trichostatin A enhanced the transcriptional activity of both BacCMV-GFP and BacFLT-GFP. Thus, in this study histone deacetylation appears to be a central mechanism for the silencing of baculovirus, independently of the promoter utilized. In vivo transcriptional targeting was demonstrated in adult rat retinal vasculature by intravitreal delivery of BacFLT-GFP and immunohistochemical staining with von Willebrand factor (vWF). Analysis by fluorescence microscopy and deconvolved three-dimensional confocal microscopy of retinal whole mounts obtained after 3 days of baculovirus injection showed that most GFP-expressing cells localized to the inner limiting membrane (ILM) and ganglion cell layer (GCL) and colocalize with vWF (70%, n = 10) in blood vessels, confirming the endothelial phenotype of the transduced cells.

Conclusion

Taken together, our results indicate that the restricted expression in endothelial cells mediated by the flt-1 promoter is not affected by the context of the baculovirus genome and demonstrate the potential of using recombinant baculovirus for transcriptional targeted gene expression into the eye vasculature.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gruchala M, Roy H, Bhardwaj S, Yla-Herttuala S: Gene therapy for cardiovascular diseases. Curr Pharm Des. 2004, 10 (4): 407-423. 10.2174/1381612043453379.PubMedCrossRef Gruchala M, Roy H, Bhardwaj S, Yla-Herttuala S: Gene therapy for cardiovascular diseases. Curr Pharm Des. 2004, 10 (4): 407-423. 10.2174/1381612043453379.PubMedCrossRef
2.
go back to reference Dutour A, Rigaud M: Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies. Anticancer Res. 2005, 25 (6B): 3799-3807.PubMed Dutour A, Rigaud M: Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies. Anticancer Res. 2005, 25 (6B): 3799-3807.PubMed
3.
go back to reference Baker AH, Kritz A, Work LM, Nicklin SA: Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol. 2005, 90 (1): 27-31. 10.1113/expphysiol.2004.028126.PubMedCrossRef Baker AH, Kritz A, Work LM, Nicklin SA: Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol. 2005, 90 (1): 27-31. 10.1113/expphysiol.2004.028126.PubMedCrossRef
4.
go back to reference Liu Y, Deisseroth A: Tumor vascular targeting therapy with viral vectors. Blood. 2006, 107 (8): 3027-3033. 10.1182/blood-2005-10-4114.PubMedCrossRef Liu Y, Deisseroth A: Tumor vascular targeting therapy with viral vectors. Blood. 2006, 107 (8): 3027-3033. 10.1182/blood-2005-10-4114.PubMedCrossRef
5.
go back to reference Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003, 4 (5): 346-358. 10.1038/nrg1066.PubMedCrossRef Thomas CE, Ehrhardt A, Kay MA: Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003, 4 (5): 346-358. 10.1038/nrg1066.PubMedCrossRef
6.
go back to reference Loser P, Huser A, Hillgenberg M, Kumin D, Both GW, Hofmann C: Advances in the development of non-human viral DNA-vectors for gene delivery. Curr Gene Ther. 2002, 2 (2): 161-171. 10.2174/1566523024605555.PubMedCrossRef Loser P, Huser A, Hillgenberg M, Kumin D, Both GW, Hofmann C: Advances in the development of non-human viral DNA-vectors for gene delivery. Curr Gene Ther. 2002, 2 (2): 161-171. 10.2174/1566523024605555.PubMedCrossRef
7.
go back to reference Kost TA, Condreay JP, Jarvis DL: Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005, 23 (5): 567-575. 10.1038/nbt1095.PubMedPubMedCentralCrossRef Kost TA, Condreay JP, Jarvis DL: Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005, 23 (5): 567-575. 10.1038/nbt1095.PubMedPubMedCentralCrossRef
8.
go back to reference Boyce FM, Bucher NL: Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci U S A. 1996, 93 (6): 2348-2352. 10.1073/pnas.93.6.2348.PubMedPubMedCentralCrossRef Boyce FM, Bucher NL: Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci U S A. 1996, 93 (6): 2348-2352. 10.1073/pnas.93.6.2348.PubMedPubMedCentralCrossRef
9.
go back to reference Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M: Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A. 1995, 92 (22): 10099-10103. 10.1073/pnas.92.22.10099.PubMedPubMedCentralCrossRef Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M: Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A. 1995, 92 (22): 10099-10103. 10.1073/pnas.92.22.10099.PubMedPubMedCentralCrossRef
10.
go back to reference Kim S, Lin H, Barr E, Chu L, Leiden JM, Parmacek MS: Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest. 1997, 100 (5): 1006-1014.PubMedPubMedCentralCrossRef Kim S, Lin H, Barr E, Chu L, Leiden JM, Parmacek MS: Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest. 1997, 100 (5): 1006-1014.PubMedPubMedCentralCrossRef
11.
go back to reference Griscelli F, Gilardi-Hebenstreit P, Hanania N, Franz WM, Opolon P, Perricaudet M, Ragot T: Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors. Hum Gene Ther. 1998, 9 (13): 1919-1928.PubMedCrossRef Griscelli F, Gilardi-Hebenstreit P, Hanania N, Franz WM, Opolon P, Perricaudet M, Ragot T: Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors. Hum Gene Ther. 1998, 9 (13): 1919-1928.PubMedCrossRef
12.
go back to reference Peng KW: Strategies for targeting therapeutic gene delivery. Mol Med Today. 1999, 5 (10): 448-453. 10.1016/S1357-4310(99)01579-8.PubMedCrossRef Peng KW: Strategies for targeting therapeutic gene delivery. Mol Med Today. 1999, 5 (10): 448-453. 10.1016/S1357-4310(99)01579-8.PubMedCrossRef
13.
go back to reference Saukkonen K, Hemminki A: Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther. 2004, 4 (5): 683-696. 10.1517/14712598.4.5.683.PubMedCrossRef Saukkonen K, Hemminki A: Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther. 2004, 4 (5): 683-696. 10.1517/14712598.4.5.683.PubMedCrossRef
14.
go back to reference Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 1999, 13 (1): 9-22.PubMed Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 1999, 13 (1): 9-22.PubMed
15.
go back to reference Shibuya M, Claesson-Welsh L: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006, 312 (5): 549-560. 10.1016/j.yexcr.2005.11.012.PubMedCrossRef Shibuya M, Claesson-Welsh L: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006, 312 (5): 549-560. 10.1016/j.yexcr.2005.11.012.PubMedCrossRef
16.
go back to reference Morishita K, Johnson DE, Williams LT: A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem. 1995, 270 (46): 27948-27953. 10.1074/jbc.270.46.27948.PubMedCrossRef Morishita K, Johnson DE, Williams LT: A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem. 1995, 270 (46): 27948-27953. 10.1074/jbc.270.46.27948.PubMedCrossRef
17.
go back to reference Cajero-Juarez M, Avila B, Ochoa A, Garrido-Guerrero E, Varela-Echavarria A, Martinez de la Escalera G, Clapp C: Immortalization of bovine umbilical vein endothelial cells: a model for the study of vascular endothelium. Eur J Cell Biol. 2002, 81 (1): 1-8. 10.1078/0171-9335-00213.PubMedCrossRef Cajero-Juarez M, Avila B, Ochoa A, Garrido-Guerrero E, Varela-Echavarria A, Martinez de la Escalera G, Clapp C: Immortalization of bovine umbilical vein endothelial cells: a model for the study of vascular endothelium. Eur J Cell Biol. 2002, 81 (1): 1-8. 10.1078/0171-9335-00213.PubMedCrossRef
18.
go back to reference Strahl BD, Allis CD: The language of covalent histone modifications. Nature. 2000, 403 (6765): 41-45. 10.1038/47412.PubMedCrossRef Strahl BD, Allis CD: The language of covalent histone modifications. Nature. 2000, 403 (6765): 41-45. 10.1038/47412.PubMedCrossRef
19.
go back to reference Newell-Price J, Clark AJ, King P: DNA methylation and silencing of gene expression. Trends Endocrinol Metab. 2000, 11 (4): 142-148. 10.1016/S1043-2760(00)00248-4.PubMedCrossRef Newell-Price J, Clark AJ, King P: DNA methylation and silencing of gene expression. Trends Endocrinol Metab. 2000, 11 (4): 142-148. 10.1016/S1043-2760(00)00248-4.PubMedCrossRef
20.
go back to reference Sarkis C, Serguera C, Petres S, Buchet D, Ridet JL, Edelman L, Mallet J: Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci U S A. 2000, 97 (26): 14638-14643. 10.1073/pnas.260472897.PubMedPubMedCentralCrossRef Sarkis C, Serguera C, Petres S, Buchet D, Ridet JL, Edelman L, Mallet J: Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci U S A. 2000, 97 (26): 14638-14643. 10.1073/pnas.260472897.PubMedPubMedCentralCrossRef
21.
go back to reference Spenger A, Ernst W, Condreay JP, Kost TA, Grabherr R: Influence of promoter choice and trichostatin A treatment on expression of baculovirus delivered genes in mammalian cells. Protein Expr Purif. 2004, 38 (1): 17-23. 10.1016/j.pep.2004.08.001.PubMedCrossRef Spenger A, Ernst W, Condreay JP, Kost TA, Grabherr R: Influence of promoter choice and trichostatin A treatment on expression of baculovirus delivered genes in mammalian cells. Protein Expr Purif. 2004, 38 (1): 17-23. 10.1016/j.pep.2004.08.001.PubMedCrossRef
22.
go back to reference Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003, 133 (7 Suppl): 2485S-2493S.PubMed Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003, 133 (7 Suppl): 2485S-2493S.PubMed
23.
go back to reference Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994, 91 (25): 11797-11801. 10.1073/pnas.91.25.11797.PubMedPubMedCentralCrossRef Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A. 1994, 91 (25): 11797-11801. 10.1073/pnas.91.25.11797.PubMedPubMedCentralCrossRef
24.
go back to reference Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF, Baker AH: Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension. 2001, 38 (1): 65-70.PubMedCrossRef Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF, Baker AH: Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension. 2001, 38 (1): 65-70.PubMedCrossRef
25.
go back to reference Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C: Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol. 2004, 66 (1-2): 129-138. 10.1023/B:NEON.0000013495.08168.8f.PubMedCrossRef Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C: Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol. 2004, 66 (1-2): 129-138. 10.1023/B:NEON.0000013495.08168.8f.PubMedCrossRef
26.
go back to reference Yoshida M, Horinouchi S: Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann N Y Acad Sci. 1999, 886: 23-36. 10.1111/j.1749-6632.1999.tb09397.x.PubMedCrossRef Yoshida M, Horinouchi S: Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann N Y Acad Sci. 1999, 886: 23-36. 10.1111/j.1749-6632.1999.tb09397.x.PubMedCrossRef
27.
go back to reference Sakamoto T, Ikeda Y, Yonemitsu Y: Gene targeting to the retina. Adv Drug Deliv Rev. 2001, 52 (1): 93-102. 10.1016/S0169-409X(01)00191-0.PubMedCrossRef Sakamoto T, Ikeda Y, Yonemitsu Y: Gene targeting to the retina. Adv Drug Deliv Rev. 2001, 52 (1): 93-102. 10.1016/S0169-409X(01)00191-0.PubMedCrossRef
28.
go back to reference Hofmann C, Strauss M: Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 1998, 5 (4): 531-536. 10.1038/sj.gt.3300607.PubMedCrossRef Hofmann C, Strauss M: Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther. 1998, 5 (4): 531-536. 10.1038/sj.gt.3300607.PubMedCrossRef
29.
go back to reference Haeseleer F, Imanishi Y, Saperstein DA, Palczewski K: Gene transfer mediated by recombinant baculovirus into mouse eye. Invest Ophthalmol Vis Sci. 2001, 42 (13): 3294-3300.PubMedPubMedCentral Haeseleer F, Imanishi Y, Saperstein DA, Palczewski K: Gene transfer mediated by recombinant baculovirus into mouse eye. Invest Ophthalmol Vis Sci. 2001, 42 (13): 3294-3300.PubMedPubMedCentral
30.
go back to reference Li Y, Yang Y, Wang S: Neuronal gene transfer by baculovirus-derived vectors accommodating a neurone-specific promoter. Exp Physiol. 2005, 90 (1): 39-44. 10.1113/expphysiol.2004.028217.PubMedCrossRef Li Y, Yang Y, Wang S: Neuronal gene transfer by baculovirus-derived vectors accommodating a neurone-specific promoter. Exp Physiol. 2005, 90 (1): 39-44. 10.1113/expphysiol.2004.028217.PubMedCrossRef
31.
go back to reference Blann AD: Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost. 2006, 95 (1): 49-55.PubMed Blann AD: Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost. 2006, 95 (1): 49-55.PubMed
32.
go back to reference Wang CY, Li F, Yang Y, Guo HY, Wu CX, Wang S: Recombinant baculovirus containing the diphtheria toxin a gene for malignant glioma therapy. Cancer Res. 2006, 66 (11): 5798-5806. 10.1158/0008-5472.CAN-05-4514.PubMedCrossRef Wang CY, Li F, Yang Y, Guo HY, Wu CX, Wang S: Recombinant baculovirus containing the diphtheria toxin a gene for malignant glioma therapy. Cancer Res. 2006, 66 (11): 5798-5806. 10.1158/0008-5472.CAN-05-4514.PubMedCrossRef
33.
go back to reference Airenne KJ, Hiltunen MO, Turunen MP, Turunen AM, Laitinen OH, Kulomaa MS, Yla-Herttuala S: Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gene Ther. 2000, 7 (17): 1499-1504. 10.1038/sj.gt.3301269.PubMedCrossRef Airenne KJ, Hiltunen MO, Turunen MP, Turunen AM, Laitinen OH, Kulomaa MS, Yla-Herttuala S: Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gene Ther. 2000, 7 (17): 1499-1504. 10.1038/sj.gt.3301269.PubMedCrossRef
34.
go back to reference Ma L, Tamarina N, Wang Y, Kuznetsov A, Patel N, Kending C, Hering BJ, Philipson LH: Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes. 2000, 49 (12): 1986-1991. 10.2337/diabetes.49.12.1986.PubMedCrossRef Ma L, Tamarina N, Wang Y, Kuznetsov A, Patel N, Kending C, Hering BJ, Philipson LH: Baculovirus-mediated gene transfer into pancreatic islet cells. Diabetes. 2000, 49 (12): 1986-1991. 10.2337/diabetes.49.12.1986.PubMedCrossRef
35.
go back to reference Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002, 1 (4): 287-299. 10.1038/nrd772.PubMedCrossRef Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002, 1 (4): 287-299. 10.1038/nrd772.PubMedCrossRef
36.
go back to reference Okada T, Uchibori R, Iwata-Okada M, Takahashi M, Nomoto T, Nonaka-Sarukawa M, Ito T, Liu Y, Mizukami H, Kume A, Kobayashi E, Ozawa K: A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. Mol Ther. 2006, 13 (4): 738-746. 10.1016/j.ymthe.2005.11.010.PubMedCrossRef Okada T, Uchibori R, Iwata-Okada M, Takahashi M, Nomoto T, Nonaka-Sarukawa M, Ito T, Liu Y, Mizukami H, Kume A, Kobayashi E, Ozawa K: A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. Mol Ther. 2006, 13 (4): 738-746. 10.1016/j.ymthe.2005.11.010.PubMedCrossRef
37.
go back to reference Imler JL, Dupuit F, Chartier C, Accart N, Dieterle A, Schultz H, Puchelle E, Pavirani A: Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Ther. 1996, 3 (1): 49-58.PubMed Imler JL, Dupuit F, Chartier C, Accart N, Dieterle A, Schultz H, Puchelle E, Pavirani A: Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Ther. 1996, 3 (1): 49-58.PubMed
38.
go back to reference Ring CJ, Harris JD, Hurst HC, Lemoine NR: Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther. 1996, 3 (12): 1094-1103.PubMed Ring CJ, Harris JD, Hurst HC, Lemoine NR: Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther. 1996, 3 (12): 1094-1103.PubMed
39.
go back to reference Shi Q, Wang Y, Worton R: Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther. 1997, 8 (4): 403-410.PubMedCrossRef Shi Q, Wang Y, Worton R: Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther. 1997, 8 (4): 403-410.PubMedCrossRef
40.
go back to reference Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP: Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999, 40 (9): 2115-2121.PubMed Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP: Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999, 40 (9): 2115-2121.PubMed
41.
go back to reference Shih SC, Ju M, Liu N, Smith LE: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest. 2003, 112 (1): 50-57. 10.1172/JCI200317808.PubMedPubMedCentralCrossRef Shih SC, Ju M, Liu N, Smith LE: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest. 2003, 112 (1): 50-57. 10.1172/JCI200317808.PubMedPubMedCentralCrossRef
Metadata
Title
In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter
Authors
Agustín Luz-Madrigal
Carmen Clapp
Jorge Aranda
Luis Vaca
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-4-88

Other articles of this Issue 1/2007

Virology Journal 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine